Table 1.
Baseline patients characteristics (N = 412).
| N or median | % or range | |
|---|---|---|
| Age | 73 | 65–78 |
| Sex | ||
| Male | 239 | 58 |
| Female | 173 | 42 |
| Therapy related | 73 | 18 |
| ECOG | ||
| 0–1 | 248 | 81 |
| 2 | 59 | 19 |
| Percentage of bone marrow blasts | ||
| Global | 10 | 6–16 |
| AML | 25 | 21–30 |
| WHO diagnosis | ||
| AML | 61 | 15 |
| MDS | ||
| MDS-U | 10 | 2 |
| MDS (RS)/MDS-MD | 52 | 13 |
| MDS-EB | 263 | 64 |
| CMML | 26 | 6 |
| Cytogenetic risk | ||
| MDS | ||
| Favorable | 133 | 41 |
| Intermediate | 60 | 18 |
| Poor | 125 | 38 |
| Failure a | 7 | 2 |
| CMML | ||
| Favorable | 16 | 62 |
| Intermediate | 3 | 11 |
| Poor | 7 | 27 |
| AML | ||
| Intermediate | 39 | 64 |
| Poor | 21 | 34 |
| Failure a | 1 | 2 |
| IPSS-R risk category | ||
| Good | 6 | 2 |
| Intermediate | 74 | 23 |
| High | 238 | 73 |
| NA | 7 | 2 |
| Hemoglobin (g/dl) | 9.1 | 8.2–10.2 |
| Hb <9 g/dl | 212 | 51 |
| ANC (×109/l) | 1 | 0.5–2.3 |
| ANC <0.5 × 109/l | 116 | 28 |
| Platelets (×109/l) | 53 | 28–102 |
AML, acute myeloid leukemia; ANC, absolute neutrophil count; CMML, chronic myelomonocytic leukemia; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; IPSS-R, International Prognostic Score System–Revised; MDS-EB, myelodysplastic syndrome with excess of blasts; MDS-MD, myelodysplastic syndrome with multilineage dysplasia; MDS-RS, myelodysplastic syndrome with ring sideroblasts; MDS-U, myelodysplastic syndrome with unilineage dysplasia; WHO, World Health Organization.
a
Failure: no metaphases were obtained.